Obtained US invention patent grants, and entered international market with 20 years exclusive right
General Agent of Taiwan
Early detection, early treatment, and improved postoperative survival rate
US FDA Orphan Drug Designation granted, Phase I/II clinical trials in progress
General Agent of Taiwan
We uphold the principle of good faith, care for the society, develop innovative precision medical technology, and rapidly circulate the translational R&D products to benefit the patients.
Precision trace the formation of liver cancer in order to assists doctors make prescription and recommendations...
More detailstreats intermediate and advanced liver cancer. Combined with TACE, it can effectively block tumor angiogenesis; combined...
More detailsA characteristic new drug repairs the urethral wall through oral administration, and prevents damage...
More details